Abstract
Effects of somatostatin on fasting and arginine- or tolbutamide-stimulated insulin release were studied in four patients with insulinoma. Somatostatin (bolus or bolus + infusion) reduced fasting insulin values in all patients; insulin response to tolbutamide was partially reduced in two patients; somatostatin bolus impaired the insulin response to arginine. Fasting glucagon levels and glucagon response to arginine were also reduced by somatostatin. These results indicate the potential usefulness of somatostatin in the diagnosis of insulinoma even if its effect on insulin is only partial.
Similar content being viewed by others
References
Siler T.M., Vanderberg G., Yen S.S.C., Brazeau P., Vale W., Guillemin R. Inhibition of growth hormone release in human by somatostatin. J. Clin. Endocrinol. Metab. 37: 632, 1973.
Hall R., Schally A.V., Evered D., Kastin A.J., Mortimer C.M., Tunbridge W.M.G., Besser G.M., Coy D.M., Goldie D.J., McNeilly A.S., Phenekos C., Weightan D. Action of growth hormone release inhibitory hormone in healthy men and in acromegaly. Lancet 1: 581, 1973.
Copinschi G., Virasoro E., Vanhaelst L., Leclercq R., Golstein J., L’Hermite M. Specific inhibition by somatostatin of growth hormone release after hypoglycemia in normal men. Clin. Endocrinol. (Oxf.) 3: 441, 1974.
Alberti K.G.M., Christensen N.J., Christensen S.E., Prange Hansen A.A., Iversen J., Lundbaek H.K., Seyer-Hansen J., Orskow H. Inhibiton of insulin secretion by somatostatin. Lancet 2: 1299, 1973.
Curry D.L., Bennet L.L., Li C.M. Direct inhibition of insulin secretion by synthetic somatostatin. Biochem. Biophys. Res. Commun. 58: 885, 1974.
Fujmoto W.Y., Ensick J.W., Williams R.M. Somatostatin inhibits insulin and glucagon release by monolayer cells culture of rat endocrine pancreas. Life Sci. 16: 1999, 1974.
Koerker D., Ruch W., Chideckel G., Palmer J., Goodner C., Ensick J.E., Gale C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184: 482, 1974.
Yen S.S.C, Siler T.M., De Vane G.W. Effect of somatostatin in patients with acromegaly. N. Engl. J. Med. 290: 935, 1974.
Besser G.M., Mortimer C.M., Larr D., Schally A.V., Coy D.H., Evered D., Kastin A.J., Tunbridge W.M.G., Thorner M.O., Hall R. Growth hormone release inhibiting hormone in acromegaly. Br. J. Med. 1: 352, 1974.
Christensen S.E., Hansen A.P., Lunbaek K., Orskow M., Sayer-Hansen K. Somatostatin and insulinoma. Lancet 1: 1426, 1975.
Curnow R.T., Carey R.M., Taylor A., Johanson A., Murad F. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet cell carcinoma. N. Engl. J. Med. 292: 1385, 1975.
Lorenzi M., Gerich J.E., Karam J.M., Forsham S.M. Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinoma: a possible diagnostic tool. J. Clin. Endocrinol. Metab. 40: 1121, 1975.
Berchtold P., Berger M., Wiegenman W., Cuppers M.J., Grunneklee D., Reminwein D., Gries F.A., Zimmermann M. Serum insulin suppression by somatostatin, diazoxide and Phenytoin in insulinoma patients. V International Congress of Endocrinology, Hamburg July 18-24, 1976, Abstract 229.
Scuro L.A., Lo Cascio V., Adami S., Galvanini G., Bianchi I., Cominacini L., Corgnati A. Somatostatin inhibition of insulin secretion in insulin producing tumors. Metabolism 6: 603, 1976.
Hoffman W.S. A rapid photoelectric method for the determination of glucose in blood and urine. J. Biochem. (Tokyo), 120: 51, 1937.
Hales C.N., Randle P.J. Immunoassay of insulin with insulin antibody precipitate. Biochem. J. 88: 137, 1963.
Aguilar-Parada E., Eisentraut A.M. Unger R.H. Pancreatic secretion in normal and diabetic subjects. Am. J. Med. Sci. 257: 415, 1969.
Fallucca F., Tamburrano S., Gambardella S., Menzinger G. Response of islet cells tumors to enterohormones. Horm. Metab. Res. (Suppl. 6) 34, 1976.
Author information
Authors and Affiliations
Additional information
Kindly supplied by Serono SPA.
Rights and permissions
About this article
Cite this article
Fallucca, F., Mirabella, C., Tamburrano, G. et al. Effects of somatostatin on insulin and glucagon in patients with insulinoma. J Endocrinol Invest 2, 257–260 (1979). https://doi.org/10.1007/BF03350412
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350412